Cassava Sciences completes dosing in open-label study of simufilam

Cassava Sciences announced the completion of drug administration in an open-label study of simufilam for Alzheimer’s disease. This study was designed to evaluate long-term drug safety and to measure cognitive changes over 12 months in approximately 200 patients with mild-to-moderate Alzheimer’s disease treated with open-label simufilam 100 mg twice daily. Simufilam is Cassava Sciences’ oral drug candidate for Alzheimer’s disease dementia. To ensure the highest integrity of data analysis, outside biostatisticians with specific expertise in Alzheimer’s disease will conduct an independent statistical analysis on the clinical dataset. Cassava Sciences may announce study results approximately year-end 2022, pending completion of a study report by outside biostatisticians.